The 2011 Import and Export Market for Medicaments Containing Hormones, Their Derivatives, and Other Steriods Used as Hormones Excluding Antibiotics and Their Derivatives in Spain

On the demand side, exporters and strategic planners focusing on medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives in Spain face a number of questions. Which countries are supplying medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives to Spain? How important is Spain compared to others in terms of the entire global and regional market? How much do the imports of medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives vary from one country of origin to another in Spain? On the supply side, Spain also exports medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives. Which countries receive the most exports from Spain? How are these exports concentrated across buyers? What is the value of these exports and which countries are the largest buyers?

This report was created for strategic planners, international marketing executives and import/export managers who are concerned with the market for medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives in Spain. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics which appear several years after the fact. I have developed a methodology, based on macroeconomic and trade models, to estimate the market for medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives for those countries serving Spain via exports, or supplying from Spain via imports. It does so for the current year based on a variety of key historical indicators and econometric models.

In what follows, Chapter 2 begins by summarizing where Spain fits into the world market for imported and exported medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives. The total level of imports and exports on a worldwide basis, and those for Spain in particular, is estimated using a model which aggregates across over 150 key country markets and projects these to the current year. From there, each country represents a percent of the world market. This market is served from a number of competitive countries of origin. Based on both demand- and supply-side dynamics, market shares by country of origin are then calculated across each country market destination. These shares lead to a volume of import and export values for each country and are aggregated to regional and world totals. In doing so, we are able to obtain maximum likelihood estimates of both the value of each market and the share that Spain is likely to receive this year. From these figures, rankings are calculated to allow managers to prioritize Spain compared to other major country markets. In this way, all the figures provided in this report are forecasts that can be combined with internal information sources for strategic planning purposes.

After the worldwide summary in Chapter 2 of both imports and exports of medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives, Chapter 3 goes into detail on imports, but for each major country of origin serving Spain. A “major” market is defined as a country where Spain represents a substantially large share of either imports or exports. For each major country exporting to Spain, one can thus observe how important Spain is to that exporting country compared to other countries of the world. Chapter 4 does the same, but for exports of medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives originating from Spain, for each major country of destination. In doing so, one can discover the share that Spain has in each major market; this share value is often used as a measure of competitiveness for Spain. In all cases, the total dollar volume and percentage share values by major trading partner are provided. Combined, Chapters 3 and 4 present a the total picture for imports and exports of medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives to and from Spain to and from all other major countries in the world. "Medicaments Containing Hormones, Their Derivatives, and Other Steriods Used as Hormones Excluding Antibiotics and Their Derivatives" as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3). The SITC code that defined "medicaments containing hormones, their derivatives, and other steriods used as hormones excluding antibiotics and their derivatives" is 5422 . SHOW LESS READ MORE >

1 INTRODUCTION AND METHODOLOGY
2 SPAIN AND THE WORLD MARKET
2.1 Imports in Spain in 2011
2.2 Exports from Spain in 2011
3 IMPORTS IN SPAIN
3.1 Asia
3.1.1 Japan
3.2 Europe
3.2.1 Austria
3.2.2 Belgium
3.2.3 Denmark
3.2.4 France
3.2.5 Germany
3.2.6 Greece
3.2.7 Ireland
3.2.8 Italy
3.2.9 Portugal
3.2.10 Sweden
3.2.11 Switzerland
3.2.12 the Netherlands
3.2.13 the United Kingdom
3.3 North America & the Caribbean
3.3.1 Canada
3.3.2 the United States
3.4 Oceana
3.4.1 Australia
4 EXPORTS FROM SPAIN
4.1 Africa
4.1.1 Cameroon
4.1.2 Malawi
4.1.3 Morocco
4.1.4 South Africa
4.1.5 Sudan
4.1.6 Tanzania
4.2 Asia
4.2.1 China
4.2.2 Japan
4.2.3 Philippines
4.2.4 South Korea
4.2.5 Taiwan
4.3 Europe
4.3.1 Austria
4.3.2 Belgium
4.3.3 Croatia
4.3.4 Cyprus
4.3.5 Denmark
4.3.6 Estonia
4.3.7 Finland
4.3.8 France
4.3.9 Germany
4.3.10 Greece
4.3.11 Hungary
4.3.12 Iceland
4.3.13 Ireland
4.3.14 Italy
4.3.15 Norway
4.3.16 Poland
4.3.17 Romania
4.3.18 Russia
4.3.19 Slovakia
4.3.20 Slovenia
4.3.21 Sweden
4.3.22 Switzerland
4.3.23 the Netherlands
4.3.24 the United Kingdom
4.3.25 Ukraine
4.4 Latin America
4.4.1 Argentina
4.4.2 Brazil
4.4.3 Colombia
4.4.4 Costa Rica
4.4.5 Ecuador
4.4.6 Guatemala
4.4.7 Mexico
4.4.8 Panama
4.4.9 Peru
4.5 North America & the Caribbean
4.5.1 Canada
4.5.2 the United States
4.5.3 Trinidad and Tobago
4.6 Oceana
4.6.1 New Zealand
4.7 the Middle East
4.7.1 Bahrain
4.7.2 Iran
4.7.3 Oman
4.7.4 Pakistan
4.7.5 Qatar
4.7.6 Saudi Arabia
4.7.7 Turkey
5 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS
5.1 Disclaimers & Safe Harbor
5.2 ICON Group Ltd. User Agreement Provisions